Speakers

Brian Avanzino is Director of Discovery Research at Rondo Therapeutics where he leads teams focused on the discovery and development of novel multispecific antibodies for the treatment of solid tumors. Previously, he was at Amgen and Teneobio where he led and advanced several T cell engager...

Philip Beer is a physician scientist, cancer biologist and oncology drug developer. He started his professional career as a haematologist with over 16 years frontline healthcare experience including clinical haemato-oncology, pathology and molecular diagnostics. This was followed by 8 years in...

Gordon Freeman, PhD, Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School, is renowned for discovering the PD-L1 and PD-L2 proteins. Dr. Freeman showed that PD-L1 and PD-L2 bound to PD-1 to turn off the immune response and that blockade of PD-L1/PD-1 enhanced immune...

Dr. Gee is Chief Research Officer at 3T Biosciences. He is co-founder of 3T Biosciences and an internationally recognized expert and pioneer in the field of pHLA targeting via T cell receptors and bispecific T cell engagers. Dr. Gee brings more than a decade of domain expertise across the...

I lead the clinical development of HIV broadly neutralizing monoclonal antibodies (bnAbs) for HIV prevention at the HVTN (HIV Vaccine Trials Network) headquarters at the Fred Hutch Cancer Center in Seattle, WA, USA.

Rajarsi Gupta is an Assistant Professor at Stony Brook Medicine, specializing in the fields of computational pathology and immuno-oncology. His research focuses on biomarker discovery, development of novel image analysis methodology, and clinical translation for laboratory medicine and precision...

Sophia Humphreys is an innovative, and dedicated Pharmacy executive with twenty plus years of pharmacy leadership experience. She is a nationally renowned leader for Medication Utilization Management, P&L and Pharmacy Spend Management. She uses her exceptional financial analysis skills and...

Jayasree K. Iyer is the CEO of the Access to Medicine Foundation, where she leads its mission to drive change in global healthcare by engaging pharmaceutical companies to expand access to essential medicines in low- and middle-income countries. With expertise in addressing complex issues like drug...

Christopher Kemball received a B.A. in Biochemical Sciences from Harvard University and a Ph.D. in Immunology & Microbial Pathogenesis from Emory University. He conducted postdoctoral research at The Scripps Research Institute and investigated how coxsackievirus impairs antiviral T cell...

J.P. Li brings more than a decade of domestic and international experience across higher education, banking, healthcare, and venture capital (VC) and private equity (PE). He began his entrepreneurial career by acquiring and scaling a Texas-based business with divisions in building materials...

Alex Macpherson is Executive Director of Novel Platforms within Lilly Small Molecule Discovery at Eli Lilly & Co. in San Diego, where he leads a team tasked with inventing new technologies to change how Lilly prosecutes small molecule targets - with a focus on stabilizing protein conformations...

Tatjana leads the Protein Sciences team at Rondo Therapeutics, an IO biotech company developing novel therapeutics for the treatment of solid tumors. Her team focuses on the development of antibodies advancing drug candidates from discovery stage to IND enabling studies. Tatjana has over a decade...

Dr. Alessandro Sette has devoted more than 35 years of study towards understanding the immune response, measuring immune activity, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. The laboratory is defining in chemical terms the specific ...

Andrew Tsourkas, Ph.D. is a Professor and Undergraduate Chair of Bioengineering at the University of Pennsylvania.  He received his Bachelor’s degree in Mechanical Engineering in 1997 from Cornell University and his Ph.D. in Biomedical Engineering from the Georgia Tech/Emory University joint...

Li Yi, Ph.D., is Executive Director and Head of Pre-Pivotal Formulation and Process Development at Gilead Sciences, where she leads biologics drug product strategy across early development portfolios. With 17 years of experience spanning Genentech/Roche, AbbVie, and Gilead, Dr. Yi has advanced...